Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8150MR)

This product GTTS-WQ8150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8150MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5853MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ15976MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ5047MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ13564MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ3230MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ15582MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ2168MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ3217MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW